Hybrid PET/MR in the Therapy of Cervical Cancer

Status Completed

Clinical Trial Summary

This is a two arm, single center feasibility study of 20 patients with non-metastatic cervical cancer managed with surgery and/or chemoradiation therapy at UNC Hospitals. Subjects will undergo PET/MRI scans before, during (chemoradiation group only), and after treatment.

Clinical Trial Description

The primary purpose of this study is to evaluate the feasibility of obtaining complete and interpretable hybrid PET/MR images for patients diagnosed with cervical cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01759355
Study type	Observational
Source	UNC Lineberger Comprehensive Cancer Center
Contact
Status	Completed
Phase
Start date	October 2012
Completion date	May 28, 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05013268` - Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma	Phase 1
Completed	`NCT02562729` - Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer	Phase 2
Completed	`NCT00416455` - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer	Phase 1/Phase 2
Completed	`NCT00054444` - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer	Phase 1
Recruiting	`NCT05210348` - Clinical Evaluation of Detection of High Risk HPV in Urine
Completed	`NCT00068549` - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer	Phase 1
Active, not recruiting	`NCT03983954` - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT00559377` - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer	Phase 2
Completed	`NCT00309959` - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer	Phase 2
Active, not recruiting	`NCT05613283` - Primary Cervical Cancer Screening by Self-sampling HPV Test
Completed	`NCT00064077` - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix	Phase 3
Active, not recruiting	`NCT02466971` - Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers	Phase 3
Completed	`NCT02164461` - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer	Phase 1
Completed	`NCT01807546` - Oral Rigosertib for Squamous Cell Carcinoma	Phase 2
Completed	`NCT00031993` - Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix	Phase 2
Active, not recruiting	`NCT01649089` - Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer	N/A
Completed	`NCT00499031` - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer	Phase 2
Terminated	`NCT00070317` - Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer	N/A
Not yet recruiting	`NCT04976478` - Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
Active, not recruiting	`NCT03738228` - Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer	Phase 1